ScripKite Pharma, Inc. CEO Christi Shaw is optimistic about Gilead Sciences, Inc. maintaining a leadership position in cancer cell therapy, especially as its second CAR-T therapy Tecartus appears poised
ScripGilead Sciences, Inc. entered into partnership negotiations with Immunomedics, Inc. six months ago and emerged from those discussions on 13 September with plans to buy the company for $21bn, giving
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Kite Will Partner With HiFiBiO On AML D